HDinHD: Open Source Science for the HD Research Community
The goal of HDinHD is to foster and support a collaborative community united in its drive to accelerate the development of therapeutics that will delay the onset and/or ameliorate the effects of Huntington’s disease. HDinHD seeks to achieve this through:
- Sharing HD-related primary scientific data
- Sharing analyses and computational models built from HD-related scientific data
- Providing browsing and data interrogation tools over both primary and analyzed data that facilitate data exploration and hypothesis generation
- Building a forum for HD researchers to highlight their data, tools, know-how and insight to the community
The HDinHD website – founded as a partnership between CHDI and the Coppola Lab at UCLA – is currently a joint development effort by CHDI, Bridlewood Consulting and Rancho BioSciences. As you will see when you Register for access, HDinHD highlights data and tools provided by the broader community. If you are interested in Contributing Data to HDinHD, suggest links to other HD-related scientific data or websites, or would otherwise like to provide Feedback to us, we encourage you to do so. HDinHD is for the community; please help us tailor and grow HDinHD in a direction that can make a difference to your research, and ultimately, to improve the lives of HD families.
Want to learn more about HDinHD?
| Watch a detailed video overview of HDinHD presented at the 16th Annual HD Therapeutics Conference (April 2021). The video outlines data resources and tools within HDinHD and provides a detailed demonstration of the new HD Explorer tool. |
Read the following publication introducing HDinHD: HDinHD: A Rich Data Portal for Huntington’s Disease Research, J Huntingtons Dis., 10, 405-412
Latest news and publications from around the HD Ecosystem
HDBuzz
- Turning down mismatch repair genes slows Huntington’s repeat growth in human neurons
- Huntington’s Disease Therapeutics Conference 2026 – Day 3
- Huntington’s Disease Therapeutics Conference 2026 – Day 2
- Huntington’s Disease Therapeutics Conference 2026 – Day 1
- Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
Literature
- A Two-Track Model of Huntington's Disease Pathology: Striatal Atrophy Mediates Maladaptive Immune Dysregulation
- Huntington's disease LIG1 modifier variant increases ligase fidelity and suppresses somatic CAG repeat expansion
- Surface-Engineered Precision Nano-Systems for Targeted Treatment of Huntington's Disease: A Review of Recent Advancements
- Electroencephalography biomarkers in Huntington's disease: A systematic review of resting-state and sleep EEG alterations
- Silmitasertib, an FDA-designated orphan CK2 inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington's disease mouse model
News
- Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer
- Lung disease treatment shows promise in Huntington's rat model
- Survey of Neurologists and Psychiatrists Reveals Barriers to Optimal Tetrabenazine Use
- CLASS ACTION REMINDER: Berger Montague Advises uniQure N.V. (NASDAQ: QURE ...
- AI agents in health care: What they say when we aren't listening - KevinMD.com




